| Quarterly Financials | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 62 | 68 | 71 | 77 | 73 | 88 | 65 | 109 | 88 | 108 | 97 | 117 | 95 | 108 |
| Expenses | 30 | 33 | 32 | 38 | 38 | 41 | 39 | 76 | 66 | 74 | 66 | 76 | 67 | 75 |
| EBITDA | 32 | 36 | 39 | 40 | 36 | 47 | 26 | 34 | 22 | 34 | 31 | 41 | 28 | 33 |
| Operating Profit % | 51 % | 52 % | 53 % | 50 % | 47 % | 52 % | 37 % | 29 % | 22 % | 26 % | 31 % | 33 % | 27 % | 27 % |
| Depreciation | 4 | 3 | 5 | 5 | 5 | 7 | 10 | 12 | 11 | 14 | 17 | 20 | 20 | 23 |
| Interest | 1 | 1 | 1 | 2 | 1 | 0 | 3 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit Before Tax | 28 | 32 | 33 | 34 | 29 | 39 | 14 | 17 | 6 | 15 | 8 | 16 | 3 | 6 |
| Tax | 7 | 8 | 9 | 9 | 7 | 10 | 4 | 7 | 2 | 5 | 3 | 5 | 1 | 2 |
| Net Profit | 21 | 24 | 25 | 25 | 22 | 30 | 10 | 10 | 4 | 10 | 5 | 10 | 2 | 3 |
| EPS in ₹ | 4.13 | 4.59 | 4.88 | 4.89 | 4.14 | 5.69 | 1.87 | 1.94 | 0.75 | 1.93 | 0.99 | 1.92 | 0.34 | 0.62 |
Tarsons Products
Tarsons Products
258.90
-9.20
(-3.43%)
There are 1 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
1,377.50 Cr
EPS
5.60
PE Ratio
66.91
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
464.30
52 Week Low
264.00
PB Ratio
2.20
Debt to Equity
0.49
Sector
Medical Equipment Analyst Rating and Forecast
- By Refinitiv from2 analysts
Actual
Company News
View All News
Tarsons Products reported Q2 net profit of 65 million rupees, down from 129 million rupees in the same period last year. However, the company's EBITDA increased to 261 million rupees from 235 million rupees year-over-year. EBITDA margin improved to 32.48% compared to 29.34% in the previous year's corresponding quarter.
Tarsons Products Limited reported quarterly results with standalone revenue of ₹71 crores, up 10% year-over-year, and consolidated revenue of ₹91 crores, up 8%. EBITDA margins improved to 31.2% on standalone basis and 27% on consolidated basis. However, profit after tax declined significantly to ₹3.6 crores standalone and ₹1.8 crores consolidated, compared to ₹6.5 crores and ₹4 crores respectively in the same quarter last year. Domestic revenue grew 12% to ₹48 crores while export revenue increased 3% to ₹43 crores. The company has started Phase 1 commercial production at its new Panchla facility, with Phase 2 expected in the second half of FY26. Initial revenue from cell culture products is anticipated in Q4 FY26. Management noted green shoots of recovery in the domestic market but highlighted challenges from subdued overseas demand and potential U.S. tariff impacts of up to 50% on Indian imports. The plastic labware industry has experienced moderation in growth momentum over the past 18-24 months.
Tarsons Products Limited's Board approved unaudited financial results for the quarter ended June 30, 2025. On a consolidated basis, the company reported revenue from operations of ₹913.64 million compared to ₹847.97 million in the same quarter last year. Net profit stood at ₹17.83 million versus ₹40.16 million in the previous year quarter. On a standalone basis, revenue from operations was ₹712.79 million compared to ₹648.49 million in the corresponding quarter last year, with net profit of ₹35.70 million versus ₹64.61 million. The company scheduled its 42nd Annual General Meeting for September 22, 2025, via video conferencing, with September 12, 2025 as the cut-off date for e-voting. The company manufactures plastic laboratory products and scientific instruments. During the previous financial year, the company paid excess remuneration of ₹9.38 million to its Managing Director and ₹4.3 million to its Whole Time Director, for which it is seeking approval for waiver through special resolution.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,025.30 | #1 20,907.50 | 56.75 | #1 1,759.00 | 22.62 | #1 339 | 5.03 | 57.39 | |
321.35 | 1,860.70 | 68.14 | 242.40 | 24.12 | 25 | 44.07 | 49.28 | |
258.90 | #3 1,377.50 | #9 66.91 | #2 408.40 | #3 32.64 | #2 30 | #8 -67.96 | 8.01 | |
638.90 | 1,154.20 | 56.26 | 186.60 | - | 20 | - | 53.39 | |
573.45 | 957.60 | 61.53 | 249.37 | 40.00 | 17 | -20.59 | 34.63 | |
490.00 | 588.20 | #1 31.18 | 67.10 | 13.15 | 18 | 18.92 | 33.37 | |
282.90 | 518.50 | 33.44 | 136.30 | #1 107.77 | 16 | 50.00 | 57.03 | |
296.00 | 378.10 | 47.97 | 111.80 | -1.43 | 8 | 0.00 | 51.13 | |
271.10 | 287.20 | 39.93 | 89.85 | - | 7 | #1 892.83 | 49.11 | |
272.80 | 272.60 | 66.02 | 122.10 | - | 1 | 820.00 | 51.99 |
Growth Rate
Revenue Growth
32.64 %
Net Income Growth
-30.05 %
Cash Flow Change
11.23 %
ROE
-32.18 %
ROCE
-23.98 %
EBITDA Margin (Avg.)
-14.19 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2024 | 2025 |
| Total Assets | 296 | 544 | 972 | 1,080 |
| Fixed Assets | 120 | 189 | 336 | 536 |
| Current Assets | 113 | 245 | 235 | 243 |
| Capital Work in Progress | 22 | 32 | 267 | 233 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 153 | 323 | 369 | 311 |
| Total Liabilities | 296 | 544 | 972 | 1,080 |
| Current Liabilities | 42 | 35 | 213 | 176 |
| Non Current Liabilities | 10 | 20 | 146 | 274 |
| Total Equity | 244 | 490 | 613 | 630 |
| Reserve & Surplus | 244 | 479 | 602 | 620 |
| Share Capital | 0 | 11 | 11 | 11 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2024 | 2025 |
| Net Cash Flow | -23 | 75 | -47 | 8 |
| Investing Activities | -64 | -138 | -285 | -145 |
| Operating Activities | 68 | 84 | 103 | 114 |
| Financing Activities | -27 | 130 | 136 | 39 |
Share Holding
| % Holding | Aug 2021 | Nov 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 50.99 % | 47.30 % | 47.30 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % | 47.31 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 8.16 % | 7.95 % | 8.04 % | 7.51 % | 9.52 % | 9.14 % | 5.82 % |
| DIIs | 0.00 % | 6.92 % | 6.03 % | 7.66 % | 7.39 % | 8.13 % | 8.52 % | 8.45 % | 7.38 % | 3.16 % | 2.15 % | 0.18 % | 0.12 % | 0.21 % | 0.50 % | 0.29 % | 0.04 % | 0.08 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 13.55 % | 11.50 % | 10.28 % | 9.94 % | 9.19 % | 9.56 % | 10.00 % | 11.35 % | 11.64 % | 12.77 % | 13.44 % | 13.53 % | 13.06 % | 15.37 % | 15.30 % | 15.42 % | 17.14 % |
| Others | 49.01 % | 32.23 % | 35.17 % | 34.75 % | 35.36 % | 35.37 % | 34.62 % | 34.25 % | 33.96 % | 37.90 % | 37.78 % | 30.92 % | 31.10 % | 31.39 % | 29.31 % | 27.58 % | 28.09 % | 29.65 % |
| No of Share Holders | 8 | 61 | 1,59,891 | 1,25,714 | 1,12,227 | 1,07,011 | 1,07,945 | 1,05,304 | 1,07,440 | 1,08,236 | 1,07,564 | 1,02,866 | 1,05,330 | 99,586 | 96,927 | 93,417 | 90,891 | 88,966 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Nov 2025 |  Quarterly Result Announcement | NA | 12 Nov 2025 | 289.05 | 268.10 |
| 20 Sept 2024 |  Dividend | ₹ 2.00 /share | 20 Sept 2024 | 418.95 | 468.70 |
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 465.20 | 452.15 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 406.65 | 419.00 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 364.55 | 329.95 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 386.30 | 431.20 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 371.20 | 373.10 |
| 22 Sept 2025 | Annual General Meeting | NA | 22 Sept 2025 | 373.10 | 309.15 |
Announcements
Announcement under Regulation 30 (LODR)-Investor Presentation
5 hours ago
5 hours agoResults For The Quarter And Half Year Ended September 30 202516 hours ago
16 hours agoBoard Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday November 12 202516 hours ago
16 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoBoard Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 20258 days ago
8 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 24, 2025
Sep 24, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Sep 22, 2025Reg. 34 (1) Annual Report.Sep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 31, 2025
Aug 31, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 30, 2025
Aug 30, 2025Notice Of The 42Nd Annual General Meeting Of The Company For The Financial Year Ended 31St March 2025.Aug 30, 2025
Aug 30, 2025Reg. 34 (1) Annual Report.Aug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Aug 12, 2025Announcement Under Regulation 30 (LODR) Regulations 2015Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Aug 12, 2025Adoption Of Unaudited Financial Results For The Quarter Ended 30Th June 2025Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday 12Th August 2025 For The Quarter Ended 30Th June 2025.Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Aug 06, 2025Board Meeting Intimation for Considering And Approving The Unaudited Standalone & Consolidated Financial Results Of The Company For The First Quarter Ended 30Th June 2025.Aug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 04, 2025
Aug 04, 2025Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015Jul 23, 2025
Jul 23, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJul 23, 2025
Jul 23, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 23, 2025
Jul 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-Credit RatingJun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 28, 2025
May 28, 2025Approved Annual Audited Financial Results For The Year Ended 31St March 2025May 28, 2025
May 28, 2025Board Meeting Outcome for Approved The Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March 2025May 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 25, 2025
May 25, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 24, 2025
May 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 24, 2025
May 24, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorMay 24, 2025
May 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
May 22, 2025Board Meeting Intimation for Intimation Of Notice Of Board MeetingMay 22, 2025
May 22, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.03% | 1 | -0.01% | -0.01% |
Technical Indicators
RSI(14)
Oversold 11.27
ATR(14)
Less Volatile 6.43
STOCH(9,6)
Oversold 11.10
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -1.07
ADX(14)
Strong Trend 34.97
UO(9)
Bullish 22.21
ROC(12)
Downtrend And Accelerating -7.05
WillR(14)
Oversold -97.31
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
